Low dose pilocarpine

Phase 3Small molecule

OOcuphire Pharma, Inc.

Low dose pilocarpine is one of 15 small molecule programs targeting Presbyopia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PresbyopiaActive, not recruiting

PresbyopiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Presbyopia

#DrugCompanyPhaseTrials

Bromday

BBausch Health Americas, Inc.

Alphagan

1 3

Alphagan

AbbVie

Phase 3

1 4

Isopto Carpine

AAdvanz Pharma

Phase 3

2 5

Pilocarpine Hcl

AbbVie

Phase 3

4 6

Miostat

FFalcon

Phase 2

3 7

Restasis

TTaiwan Bio Therapeutics Inc.

AGN-199201

3 9

Low dose pilocarpine

OOcuphire Pharma, Inc.

Phase 3

1 10

AGN-190584

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Presbyopia1 trial

Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia

Completed·OOcuphire Pharma, Inc.·Phase 3·NCT05646719·333 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Low dose pilocarpine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low dose pilocarpine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low dose pilocarpine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ocuphire Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOcuphire Pharma, Inc.

Low dose pilocarpine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Presbyopia1 trial

References

Drug Info

Quick Facts

Related News